These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
241 related articles for article (PubMed ID: 38553943)
1. Toxicity profiles of immune checkpoint inhibitors for recurrent or metastatic head and neck squamous cell carcinoma: A systematic review and meta-analysis. Dang S; Li X; Liu H; Zhang S; Li W Cancer Med; 2024 Apr; 13(7):e7119. PubMed ID: 38553943 [TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of immune checkpoint inhibitors in recurrent or metastatic head and neck squamous cell carcinoma: A systematic review and meta-analysis of randomized clinical trials. Dang S; Zhang S; Zhao J; Li X; Li W Cancer Med; 2023 Oct; 12(20):20277-20286. PubMed ID: 37814950 [TBL] [Abstract][Full Text] [Related]
3. Durvalumab with or without tremelimumab for patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a systematic review and meta-analysis. Han X; Zhang H; Sun K; Li J; Wu W; Liu K; Yu Z Front Immunol; 2023; 14():1302840. PubMed ID: 38299153 [TBL] [Abstract][Full Text] [Related]
4. Risk of Ophthalmic Adverse Events in Patients Treated with Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis. Hou YL; Wang DY; Hu JX; Tian RY; Wang W; Su Q; Li H; Wang YL Ocul Immunol Inflamm; 2022 Aug; 30(6):1449-1459. PubMed ID: 33970759 [TBL] [Abstract][Full Text] [Related]
5. The effects of PD-1/PD-L1 checkpoint inhibitors on recurrent/metastatic head and neck squamous cell carcinoma: a critical review of the literature and meta-analysis. Clarke E; Eriksen JG; Barrett S Acta Oncol; 2021 Nov; 60(11):1534-1542. PubMed ID: 34410881 [TBL] [Abstract][Full Text] [Related]
6. Initial analysis of the synergy of programmed cell death-1 (PD-1) inhibitor and concurrent chemoradiotherapy treatment for recurrent/metastatic head and neck squamous cell carcinoma patients. Li L; Chen L; Yan L; Guo Y; Li F; Fan M; Lan M; Lai X; Zhou J; Huang Y; Xu P; Lang J; Feng M Radiat Oncol; 2023 Jul; 18(1):109. PubMed ID: 37403098 [TBL] [Abstract][Full Text] [Related]
7. Prognostic role of programmed cell death ligand-1 expression in head and neck cancer treated with programmed cell death protein-1/programmed cell death ligand-1 inhibitors: A meta-analysis based on clinical trials. Huang Z; Zheng S; Ding S; Wei Y; Chen C; Liu X; Li H; Xia Y J Cancer Res Ther; 2021 Jul; 17(3):676-687. PubMed ID: 34269299 [TBL] [Abstract][Full Text] [Related]
8. Adverse Events of Immune Checkpoint Inhibitor-Based Therapies for Unresectable Hepatocellular Carcinoma in Prospective Clinical Trials: A Systematic Review and Meta-Analysis. Zhang Y; Wang M; Chen Q; Deng Y; Chen J; Dai Y; Luo S; Xu J; Zhao H; Cai J Liver Cancer; 2023 Dec; 12(6):521-538. PubMed ID: 38476294 [TBL] [Abstract][Full Text] [Related]
9. Immune checkpoint inhibitors in head and neck squamous cell carcinoma: A systematic review of phase-3 clinical trials. Poulose JV; Kainickal CT World J Clin Oncol; 2022 May; 13(5):388-411. PubMed ID: 35662989 [TBL] [Abstract][Full Text] [Related]
10. The safety and tolerability of combined immune checkpoint inhibitors (anti-PD-1/PD-L1 plus anti-CTLA-4): a systematic review and meta-analysis. Gu L; Khadaroo PA; Su H; Kong L; Chen L; Wang X; Li X; Zhu H; Zhong X; Pan J; Chen M BMC Cancer; 2019 Jun; 19(1):559. PubMed ID: 31182049 [TBL] [Abstract][Full Text] [Related]
11. An investigative meta-analysis on the effectiveness and safety of integrating VEGF/VEGFR inhibitors with PD-1/PD-L1 inhibitors in cases with R/M HNSCC. Wang H; Hu L; Zhang F; Fang M; Xu J; Li M; Chen Z Oral Oncol; 2024 Jun; 153():106814. PubMed ID: 38714115 [TBL] [Abstract][Full Text] [Related]
12. Toxicity profile of combined immune checkpoint inhibitors and thoracic radiotherapy in esophageal cancer: A meta-analysis and systematic review. Xu T; Liu Y; Lu X; Liang J Front Immunol; 2022; 13():1039020. PubMed ID: 36439117 [TBL] [Abstract][Full Text] [Related]
13. Programmed Death-1/Programmed Death-Ligand 1-Axis Blockade in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Stratified by Human Papillomavirus Status: A Systematic Review and Meta-Analysis. Xu Y; Zhu G; Maroun CA; Wu IXY; Huang D; Seiwert TY; Liu Y; Mandal R; Zhang X Front Immunol; 2021; 12():645170. PubMed ID: 33897693 [TBL] [Abstract][Full Text] [Related]
14. PD-1/PD-L1 inhibitor plus chemotherapy versus standard of care in the first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma. Mo DC; Huang JF; Luo PH; Chen L; Zou B; Wang HL Eur Arch Otorhinolaryngol; 2023 Jan; 280(1):1-9. PubMed ID: 35907001 [TBL] [Abstract][Full Text] [Related]
15. PD-1/PD-L1 inhibitor monotherapy in recurrent or metastatic squamous cell carcinoma of the head and neck: a meta-analysis. Chen L; Mo DC; Hu M; Zhao SJ; Yang QW; Huang ZL Am J Otolaryngol; 2022; 43(2):103324. PubMed ID: 34923281 [TBL] [Abstract][Full Text] [Related]
16. Treatment-related adverse events of immune checkpoint inhibitors combined with angiogenesis inhibitors in advanced lung cancer: A systematic review and meta-analysis. Zheng Y; Dong H; Yu Y; Hu Z; Xue C; Zhang X; Cui H Int Immunopharmacol; 2023 Oct; 123():110785. PubMed ID: 37598630 [TBL] [Abstract][Full Text] [Related]
17. A systematic review and meta-analysis of prognostic indicators in patients with head and neck malignancy treated with immune checkpoint inhibitors. Kang D; Liu S; Yuan X; Liu S; Zhang Z; He Z; Yin X; Mao H J Cancer Res Clin Oncol; 2023 Dec; 149(20):18215-18240. PubMed ID: 38078963 [TBL] [Abstract][Full Text] [Related]
18. The current advances and future directions of PD-1/PD-L1 blockade in head and neck squamous cell carcinoma (HNSCC) in the era of immunotherapy. Chen Y; Ding X; Bai X; Zhou Z; Liu Y; Zhang X; Yu J; Hu M Int Immunopharmacol; 2023 Jul; 120():110329. PubMed ID: 37207445 [TBL] [Abstract][Full Text] [Related]
19. Anti-PD-1 and Anti-PD-L1 in Head and Neck Cancer: A Network Meta-Analysis. Botticelli A; Cirillo A; Strigari L; Valentini F; Cerbelli B; Scagnoli S; Cerbelli E; Zizzari IG; Rocca CD; D'Amati G; Polimeni A; Nuti M; Merlano MC; Mezi S; Marchetti P Front Immunol; 2021; 12():705096. PubMed ID: 34434192 [TBL] [Abstract][Full Text] [Related]
20. Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a randomized, open-label, phase III study. Psyrri A; Fayette J; Harrington K; Gillison M; Ahn MJ; Takahashi S; Weiss J; Machiels JP; Baxi S; Vasilyev A; Karpenko A; Dvorkin M; Hsieh CY; Thungappa SC; Segura PP; Vynnychenko I; Haddad R; Kasper S; Mauz PS; Baker V; He P; Evans B; Wildsmith S; Olsson RF; Yovine A; Kurland JF; Morsli N; Seiwert TY; Ann Oncol; 2023 Mar; 34(3):262-274. PubMed ID: 36535565 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]